Price$325.38-0.24 (-0.07%)
01:30 PM07:45 PM
News · 26 weeks71+17%
2025-11-022026-04-26
Mix3290d
- Insider16(50%)
- SEC Filings10(31%)
- Other4(13%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by Penumbra Inc.DEFA14A - Penumbra Inc (0001321732) (Filer)
- SECSEC Form DEF 14A filed by Penumbra Inc.DEF 14A - Penumbra Inc (0001321732) (Filer)
- SECSEC Form 425 filed by Penumbra Inc.425 - Penumbra Inc (0001321732) (Subject)
- SECSEC Form 425 filed by Penumbra Inc.425 - Penumbra Inc (0001321732) (Subject)
- SECSEC Form 425 filed by Penumbra Inc.425 - Penumbra Inc (0001321732) (Subject)
- PRNew STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism PatientsALAMEDA, Calif., April 13, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations), compared to anticoagulation alone. The first-of-its kind data were presented at this week's Society of Interventional Radiology (SIR) Annual Scientific Meeting.
- INSIDERSEC Form 4 filed by Grewal Harpreet4 - Penumbra Inc (0001321732) (Issuer)
- SECSEC Form DEFM14A filed by Penumbra Inc.DEFM14A - Penumbra Inc (0001321732) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Penumbra Inc.SCHEDULE 13G/A - Penumbra Inc (0001321732) (Subject)
- INSIDERPresident Narayan Shruthi covered exercise/tax liability with 117 shares, decreasing direct ownership by 0.38% to 30,755 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDEREVP, Gen. Counsel & Secretary Roberts Johanna covered exercise/tax liability with 186 shares, decreasing direct ownership by 0.28% to 67,298 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDERChief Financial Officer Yuen Maggie covered exercise/tax liability with 186 shares, decreasing direct ownership by 1% to 18,167 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDERChief Accounting Officer Shiu Lambert covered exercise/tax liability with 150 shares, decreasing direct ownership by 0.38% to 39,323 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDERChief Financial Officer Yuen Maggie sold $832,474 worth of shares (2,432 units at $342.30), decreasing direct ownership by 12% to 18,353 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- SECSEC Form 425 filed by Penumbra Inc.425 - Penumbra Inc (0001321732) (Subject)
- SECSEC Form 10-K filed by Penumbra Inc.10-K - Penumbra Inc (0001321732) (Filer)
- SECPenumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Penumbra Inc (0001321732) (Filer)
- PRPenumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial ResultsALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024.Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024.U.S. Thrombectomy revenue of $203.1 million for the fourth quarter
- INSIDERDirector Grewal Harpreet was granted 589 shares, increasing direct ownership by 7% to 8,819 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDERDirector Bose Arani was granted 589 shares, increasing direct ownership by 106% to 1,147 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDERDirector Leeds Janet was granted 589 shares, increasing direct ownership by 10% to 6,639 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDERDirector O'Rourke Bridget was granted 589 shares, increasing direct ownership by 11% to 5,962 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDERDirector Sarna Surbhi was granted 589 shares, increasing direct ownership by 16% to 4,293 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDERDirector Wilder Thomas was granted 589 shares (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
- INSIDEREVP, Gen. Counsel & Secretary Roberts Johanna covered exercise/tax liability with 482 shares and was granted 5,260 shares, increasing direct ownership by 8% to 67,484 units (SEC Form 4)4 - Penumbra Inc (0001321732) (Issuer)
PEN FAQ
7 questionsWhat does Penumbra Inc. do?
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400...Where does PEN stock trade?
Penumbra Inc. (PEN) is listed on NYSE.What sector and industry is PEN in?
Penumbra Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Penumbra Inc. go public?
Penumbra Inc. (PEN) completed its IPO in 2015.What are analysts saying about PEN?
Penumbra Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight on 2025-12-18. Recent price targets cluster around $1500.00.What companies are similar to PEN?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare PEN side-by-side with any of them on Quantisnow.How can I track PEN on Quantisnow?
Quantisnow aggregates Penumbra Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PEN to receive live email and push alerts on every new disclosure.